Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 3/20 | 0.31 |
| ▸ | CES1 | P23141 | 3/20 | 0.31 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL306578 | 1.00 | TSHR (0.56) | TSHRALDH1A1TP53LMNANFKB1 | |
| SCHEMBL347793 | 1.00 | TSHR (0.56) | TSHRALDH1A1TP53LMNANFKB1 | |
| SCHEMBL347023 | 1.00 | TSHR (0.56) | TSHRALDH1A1TP53LMNANFKB1 | |
| SCHEMBL11255873 | 1.00 | TSHR (0.56) | TSHRALDH1A1TP53LMNANFKB1 | |
| SCHEMBL13859605 | 1.00 | TSHR (0.56) | TSHRALDH1A1TP53LMNANFKB1 | |
| SCHEMBL34211 | 1.00 | — | — | |
| SCHEMBL347787 | 1.00 | TSHR (0.56) | TSHRALDH1A1TP53LMNANFKB1 | |
| SCHEMBL305763 | 1.00 | TSHR (0.56) | TSHRALDH1A1TP53LMNANFKB1 | |
| SCHEMBL349064 | 1.00 | TSHR (0.56) | TSHRALDH1A1TP53LMNANFKB1 | |
| SCHEMBL28244416 | 1.00 | TSHR (0.56) | TSHRALDH1A1TP53LMNANFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113876595-A | Birch alcohol-based quaternary ammonium salt antibacterial organic monomer, application of composite resin of birch alcohol-based quaternary ammonium salt antibacterial organic monomer and preparation method of composite resin of birch alcohol-based quaternary ammonium salt antibacterial organic monomer | 东华大学 | 2022-01-04 | — | — | CN | claimed |
| US-12583816-B2 | Lipids for lipid nanoparticle delivery of active agents | Acuitas Therapeutics, Inc. (CA) | 2026-03-24 | — | — | US | disclosed |
| CN-112707900-B | Protein degrading agents and their use in the treatment of disease | 上海科技大学 | 2022-06-10 | — | — | CN | disclosed |
| CN-113876595-A | Birch alcohol-based quaternary ammonium salt antibacterial organic monomer, application of composite resin of birch alcohol-based quaternary ammonium salt antibacterial organic monomer and preparation method of composite resin of birch alcohol-based quaternary ammonium salt antibacterial organic monomer | 东华大学 | 2022-01-04 | — | — | CN | disclosed |
| US-20210395188-A1 | LIPIDS FOR LIPID NANOPARTICLE DELIVERY OF ACTIVE AGENTS | Acuitas Therapeutics, Inc. (CA) | 2021-12-23 | — | — | US | disclosed |
| WO-2021078301-A1 | PROTEIN DEGRADING AGENT AND USE THEREOF IN TREATMENT OF DISEASES | 上海科技大学 | 2021-04-29 | — | — | WO | disclosed |
| CN-112707900-A | Protein degradation agent and application thereof in disease treatment | 上海科技大学 | 2021-04-27 | — | — | CN | disclosed |
| WO-2020081938-A1 | LIPIDS FOR LIPID NANOPARTICLE DELIVERY OF ACTIVE AGENTS | Acuitas Therapeutics, Inc. (CA) | 2020-04-23 | — | — | WO | disclosed |
| EP-1719768-B1 | NOVEL BENZOTHIAZEPINE AND BENZOTHIEPINE COMPOUNDS | ASAHI KASEI PHARMA CORP (JP) | 2012-04-25 | — | — | EP | disclosed |
| US-20120015925-A1 | NOVEL BENZOTHIAZEPINE AND BENZOTHIEPINE COMPOUNDS | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-01-19 | — | — | US | disclosed |
| US-20050131002-A1 | Novel amide compounds and medications containing the same | KOWA COMPANY LTD. (JP) | 2005-06-16 | — | — | US | disclosed |
| EP-1535913-A1 | NOVEL QUATERNARY AMMONIUM COMPOUNDS | Asahi Kasei Pharma Corporation (JP) | 2005-06-01 | — | — | EP | disclosed |
| US-6849647-B1 | Amide compounds and medications containing the same technical field | KOWA COMPANY, LTD. (JP) | 2005-02-01 | — | — | US | disclosed |
| US-20050009805-A1 | Novel quaternary ammonium compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-01-13 | — | — | US | disclosed |
| EP-1028955-B1 | PYRIMIDINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SMITHKLINE BEECHAM PLC (GB) | 2003-07-16 | — | — | EP | disclosed |
| US-20020120139-A1 | Pyrimidinone compounds and pharmaceutical compositions containing them | HICKEY DEIRDRE MARY BERNADETTE (GB) | 2002-08-29 | — | — | US | disclosed |
| US-6417192-B1 | DRUGS WITH PYRIMIDONE COMPOUNDS INHIBITORS OF THE ENZYME LDL PLA.SUB.2 AND THEREFORE OF USE IN TREATING ATHEROSCLEROSIS. | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-07-09 | — | — | US | disclosed |
| EP-1028955-A1 | PYRIMIDINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SmithKline Beecham p.l.c. (GB) | 2000-08-23 | — | — | EP | disclosed |
| EP-0979823-A1 | NOVEL AMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME | Kowa Company Ltd. (JP) | 2000-02-16 | — | — | EP | disclosed |
| WO-1999024420-A1 | PYRIMIDINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SMITHKLINE BEECHAM PLC (GB) | 1999-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210395188-A1 | LIPIDS FOR LIPID NANOPARTICLE DELIVERY OF ACTIVE AGENTS | PHOSPHO1, NPC1, LRAT | TSHR 2461/4885ALDH1A1 1158/4885TP53 1704/4885 |
| US-20020120139-A1 | Pyrimidinone compounds and pharmaceutical compositions containing them | PLA2G7, PLA2G1B, PLA2G4C | TSHR 4310/4885ALDH1A1 960/4885TP53 4558/4885 |
| US-20050009805-A1 | Novel quaternary ammonium compounds | SLC10A1, GOT1, ACAT2 | TSHR 2727/4885ALDH1A1 1743/4885TP53 3898/4885 |
| US-12583816-B2 | Lipids for lipid nanoparticle delivery of active agents | NPC1, LDLR, SGMS1 | TSHR 2589/4885ALDH1A1 1473/4885TP53 3226/4885 |
| US-20050131002-A1 | Novel amide compounds and medications containing the same | ACAT2, SULT2A1, ACAT1 | TSHR 2127/4885ALDH1A1 1410/4885TP53 3428/4885 |
| US-20120015925-A1 | NOVEL BENZOTHIAZEPINE AND BENZOTHIEPINE COMPOUNDS | SLC10A1, SREBF1, SPTLC1 | TSHR 3208/4885ALDH1A1 1261/4885TP53 4483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.